Procurement teams evaluating Selank (5mg / 10mg) in Neuropeptide Research programs can use this spec alignment brief before requesting a quote on sulanpeptide.vip.
Selank is a synthetic heptapeptide used in laboratory research on neuropeptide signaling, immune-neural pathway models, receptor response, and peptide stability studies.
Selank is classified as a peptide anxiolytic research compound in Russian pharmacology journals with emphasis on neurotransmitter balance assays. Selank is a synthetic Tuftsin analog (TP-7) studied for effects on GABAergic modulation, enkephalin degradation, and cytokine expression in neuroimmune models.
Russian Academy of Sciences literature documents anxiolytic-like behavioral readouts in elevated plus-maze models without benzodiazepine receptor direct agonism. Plus-maze and open-field behavioral scoring, BDNF expression in hippocampus, and enkephalinase activity assays appear in Selank research papers.
Spec alignment: Enter exact strength notation (5mg / 10mg) in procurement systems—do not round kit counts. Side-by-side review of specification table, vial label, and COA prevents release errors for Selank.
Principal investigators should sign off Selank SKUs only after mechanism fit is documented in the study protocol.
Catalog identifiers for Selank: CAS 129954-34-3, Formula: C33H57N11O9. MW 751.9 g/mol, purity target ≥ 99.0%. Copy these fields into requisitions and match them line-by-line on incoming COA PDFs.
Dose planning for Selank should state mass (5mg / 10mg) or molarity derived from catalog molecular weight.
Publication methods should list Cat No. and mg strength for Selank to support reproducibility.
Molecular identifiers for Selank—CAS 129954-34-3, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing Selank should include these fields for reproducibility in Neuropeptide Research journals. Format selection for Selank affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability.
Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for Selank. QA sign-off should reference all four documents in the batch record. Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for Selank should state whether the lot COA must meet or exceed that threshold for your Neuropeptide Research assay type.
Specification alignment for Selank requires copying exact kit notation (5mg / 10mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits.
Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for Selank should state whether the lot COA must meet or exceed that threshold for your Neuropeptide Research assay type. Specification alignment for Selank requires copying exact kit notation (5mg / 10mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits.
Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for Selank. QA sign-off should reference all four documents in the batch record.
Selank from Sulan Peptide Official is for research use only (RUO)—not for human or veterinary use. Questions: Contact page or WhatsApp on sulanpeptide.vip.